Moderna COVID-19 Vaccines
Spikevax and Moderna COVID-19 Vaccine and Moderna COVID-19 Vaccine, Bivalent
On January 31, 2022, the FDA announced the second approval of a COVID-19 vaccine. The vaccine has been known as the Moderna COVID-19 Vaccine, and will now be marketed as Spikevax, for the prevention of COVID-19 in individuals 18 years of age and older.
Spikevax is a monovalent COVID-19 vaccine that is approved for use as a two-dose primary series for the prevention of COVID-19 in individuals 18 years of age and older. It is also authorized for emergency use to provide:
- A two-dose primary series to individuals 12 years through 17 years of age.
- A third primary series dose to individuals 12 years of age and older with certain kinds of immunocompromise.
Moderna COVID-19 Vaccine is a monovalent COVID-19 vaccine that is authorized for emergency use to prevent COVID-19 as a:
- Two-dose primary series for individuals 6 months of age and older.
- Third primary series dose for individuals 6 months of age and older who have been determined to have certain kinds of immunocompromise.
Moderna COVID-19 Vaccine, Bivalent is authorized for use in individuals 18 years of age and older as a single booster dose administered at least 2 months after either:
- Completion of primary vaccination with any authorized or approved monovalent COVID-19 vaccine, or
- Receipt of the most recent booster dose with any authorized or approved monovalent COVID-19 vaccine.
On February 11, 2022, in consultation with FDA, CDC issued emergency use instructions to provide information about the primary, additional, and booster doses of the Moderna COVID-19 vaccines in certain individuals.
Spikevax Information
Information | Last Updated |
---|---|
Package Insert | January 31, 2022 |
Patient Package Insert | January 31, 2022 |
Approval Letter | January 31, 2022 |
Summary Basis for Regulatory Action | January 30, 2022 |
Frequently Asked Questions (Español) | April 19, 2022 |
CDC-issued Emergency Use Instructions | February 11, 2022 |
Moderna COVID-19 Vaccine Fact Sheets (English) and FAQs
Material | Audience | Vaccine Purpose | Vaccine Recipient Group | Last Updated |
---|---|---|---|---|
Dear Healthcare Provider Letter | Healthcare Providers | Bivalent Booster | 18 years and older (gray border) | September 7, 2022 |
Important Prescribing Information for Vaccine Providers on Vial Presentation Available to Provide Doses for Ages 6 Years Through 11 Years | Healthcare Providers | Primary Series | 6 years through 11 years of age (purple border) | August 31, 2022 |
Fact Sheet | Healthcare Providers | Primary Series | 6 months through 5 years of age (magenta border) | August 31, 2022 |
Fact Sheet | Recipients and Caregivers | Primary Series | 6 months through 5 years of age (magenta border) | June 17, 2022 |
Fact Sheet | Healthcare Providers | Primary Series | 6 years through 11 years of age (teal and purple border) | August 31, 2022 |
Fact Sheet | Recipients and Caregivers | Primary Series | 6 years through 11 years of age (teal & purple border) | June 17, 2022 |
Fact Sheet | Healthcare Providers | Primary Series | 12 years and older (light blue border) | August 31, 2022 |
Fact Sheet | Healthcare Providers | Bivalent Booster | 18 years and older (gray border) | August 31, 2022 |
Fact Sheet | Recipients and Caregivers | Primary Series and Bivalent Booster | 12 years and older (primary series) and 18 years and older (booster) (black border) | August 31, 2022 |
Frequently Asked Questions on the Moderna COVID-19 Vaccine | All | All | All | February 16, 2022 |
Moderna COVID-19 Vaccine Regulatory Information
Information | Date |
---|---|
Decision Memorandum | August 31, 2022 |
Letter of Authorization (Reissued) | August 31, 2022 |
Decision Memorandum | June 17, 2022 |
Decision Memorandum | March 28, 2022 |
Decision Memorandum | January 6, 2022 |
Decision Memorandum Addendum | December 30, 2021 |
Letter Granting EUA Amendment | December 9, 2021 |
Decision Memorandum | November 19, 2021 |
Decision Memorandum Addendum | November 19, 2021 |
Decision Memorandum Addendum | November 18, 2021 |
Memorandum to the File | October 20, 2021 |
Decision Memorandum | October 20, 2021 |
Advisory Committee Meeting Information | October 14, 2021 |
Letter Granting EUA Amendment | August 30, 2021 |
Decision Memorandum | August 12, 2021 |
Letter Granting EUA Amendment | June 25, 2021 |
Letter Granting EUA Amendment | April 1, 2021 |
FDA Decision Memorandum | December 18, 2020 |
Advisory Committee Meeting Information | December 17, 2020 |
Media Materials and Webcasts
Information | Date |
---|---|
Press Conference | August 31, 2022 |
Press Release | August 31, 2022 |
Press Conference | June 17, 2022 |
Press Release | June 17, 2022 |
Advisory Committee Webcast | June 15, 2022 |
Advisory Committee Webcast | June 14, 2022 |
Media Call | March 29, 2022 |
Press Release | March 29, 2022 |
Press Release | January 31, 2022 |
Press Release | January 7, 2022 |
Press Release | November 19, 2021 |
Press Release | October 20, 2021 |
Media Call | October 20, 2021 |
Advisory Meeting Webcast | October 14, 2021 |
Press Release | August 12, 2021 |
Press Release | April 1, 2021 |
Press Release | December 18, 2020 |
Media Call | December 18, 2020 |
Advisory Committee Webcast | December 17, 2020 |
Translations of the Fact Sheet for Recipients and Caregivers
Translations of the Moderna Fact Sheet for Recipients and Caregivers for 6 months through 5 years of age
Fact Sheet | Vaccine Recipient Group | Language |
---|---|---|
HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES AUTORIZACIÓN DE USO DE EMERGENCIA DE LA VACUNA CONTRA EL COVID-19 DE MODERNA PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) EN NIÑOS DE 6 MESES A 5 AÑOS |
6 months - 5 years of age | Español (Spanish) |
给受种人和监护人的情况说明书 针对6 个月到 5 岁的个体 预防 2019冠状病毒病 (COVID-19) 的现代 COVID-19 疫苗紧急使用授权 |
6 months - 5 years of age | 中文 (Chinese, Simplified) |
수혜자와 간병인을 위한 팩트 시트 6개월에서 5세 사이의 개인에 코로나 바이러스 질병 2019(COVID-19)를 예방하기 위한 모더나 COVID-19 백신의 긴급 사용 승인 |
6 months - 5 years of age | 한국어 (Korean) |
FACT SHEET PARA SA MGA TATANGGAP AT MGA NAG-AALAGA EMERGENCY USE AUTHORIZATION NG BAKUNANG MODERNA COVID-19 UPANG MAIWASAN ANG CORONAVIRUS DISEASE 2019 (COVID-19) SA MGA INDIBIDWAL 6 NA BUWAN HANGGANG 5 TAONG GULANG |
6 months - 5 years of age | Tagalog (Tagalog) |
6 months - 5 years of age | Tiếng Việt (Vietnamese) |
Translations of the Moderna Fact Sheet for Recipients and Caregivers for 6 through 11 years of age
Fact Sheet | Vaccine Recipient Group | Language |
---|---|---|
HOJA INFORMATIVA PARA RECEPTORES Y CUIDADORES AUTORIZACIÓN DE USO DE EMERGENCIA DE LA VACUNA CONTRA EL COVID-19 DE MODERNA PARA PREVENIR LA ENFERMEDAD DEL CORONAVIRUS 2019 (COVID-19) EN NIÑOS DE 6 AÑOS A 11 AÑOS |
6 - 11 years of age | Español (Spanish) |
给受种人和监护人的情况说明书 针对6 岁到 11 岁个体 预防 2019 冠状病毒病 (COVID-19) 的现代 COVID-19 疫苗紧急使用授权 |
6 - 11 years of age | 中文 (Chinese, Simplified) |
수혜자와 간병인을 위한 팩트 시트 6세에서 11세 사이의 개인에 코로나 바이러스 질병 2019(COVID-19)를 예방하기 위한 모더나 COVID-19 백신의 긴급 사용 승인 |
6 - 11 years of age | 한국어 (Korean) |
FACT SHEET PARA SA MGA TATANGGAP AT MGA NAG-AALAGA EMERGENCY USE AUTHORIZATION NG BAKUNANG MODERNA COVID-19 UPANG MAIWASAN ANG CORONAVIRUS DISEASE 2019 (COVID-19) SA MGA 6 NA TAON HANGGANG 11 TAONG GULANG |
6 - 11 years of age | Tagalog (Tagalog) |
6 -11 years of age | Tiếng Việt (Vietnamese) |
Translations of the Moderna Fact Sheet for Recipients and Caregivers for 12 years of age and older